| Objective Observation of Yifei moxibustion treatment of chronic obstructive pulmonary disease(COPD)patients with acute exacerbation and clinical symptoms / signs,dyspnea score(MMRC),six minute walk distance(6MWD),lung function,and to evaluate its clinical efficacy,and by observing the regulatory effect of Yifei moxibustion on serum levels of IL-32 and caspase-1 and interpretation Yifei moxibustion in the treatment of chronic obstructive pulmonary disease(COPD)part of the mechanism of action.Methods Taking 120 cases of COPD stable phase were divided into experimental group and control group,60 cases were randomly divided into experimental group and control group.The experimental group in the conventional treatment based on the conventional treatment to give Yifei moxibustion treatment,the control group to maintain the original conventional treatment plan,the treatment period is 3 months.Observe the two groups of patients before and after the treatment of acute exacerbation frequency,clinical symptoms / signs,MMRC,6MWD,pulmonary function.The study on the part of the mechanism of the treatment of COPD,only 60 cases were divided into the experimental group and the control group,30 cases each.The serum levels of IL-32 and caspase-1 were detected before and 3 months of treatment.Data using SPSS20.0 for statistical analysis.Results A total of 120 patients,18 cases of shedding,in the case of a total of 102 cases,of which 50 cases of experimental group,the control group of 52 cases.Mechanism of Yifei moxibustion in the treatment of chronic obstructive pulmonary disease(COPD)selects only the 60 patients were divided into test group and control group with 30 cases in each,excluding off case 20 cases,a total of 40 cases of patients serum conform to requirements(test group 19 people,the control group(n = 21)).There was no significant difference between the two groups at baseline.1 Acute exacerbation There was no statistical difference in the acute exacerbation times between the two groups(P>0.05)before treatment,and there was no significant difference between the groups(P>0.05).The experimental group in 3 months the frequency of acute exacerbation by 1 year after conversion treatment with 1 year before the times of acute exacerbation significantly reduced(P < 0.05),control group in times of acute exacerbation compared with reduction of no statistical difference(P > 0.05).2 Clinical symptoms and signs with total score There was no significant difference in clinical symptoms between the two groups before treatment(P>0.05).There were significant differences between the 3 groups after treatment(P<0.05).After treatment,the clinical symptoms of the experimental group and the control group were significantly improved compared with those before treatment(P<0.05),and the experimental group was more significant than before(P<0.01).Individual symptoms of cough,expectoration,wheezing,chest tightness,fatigue,shortness of breath,integral compared with those before treatment has improved(P < 0.05),cyanosis integral is no statistical difference(P > 0.05).The repeated measurement analysis of variance analysis at different time points(treatment of 1 month,2 months,treatment for 3 months)between the two groups of clinical symptoms total score and individual symptoms cough,sputum,wheezing,chest tightness,shortness of breath,fatigue,cyanosis integral is reduced to a statistically significant difference(P < 0.05).3 MMRC Dyspnea scores between the two groups were not statistically significant(P>0.05)before treatment,and there was a statistically significant difference between the two groups(P<0.05).After treatment,the experimental group compared with the treatment before the reduction of dyspnea was statistically significant(P<0.05),the control group was not statistically significant difference(P>0.05).Repeated measures analysis of variance,different time points(1 months,2 months of treatment,3 months),the two groups had significantly reduced dyspnea score(P<0.05).4 6-minute walk distance There was no statistical difference between the two groups after six minutes walking distance(P>0.05),and the difference was statistically significant(P<0.05).After treatment,the experimental group six minutes walk away than before treatment significantly improved(P<0.01),compared with the control group before treatment was not statistically significant difference(P>0.05).By repeated measures analysis of variance,different time points(1months,2 months,3 months of treatment),six groups of two minutes walking distance decreased significantly(P<0.05).5 Pulmonary Function Before treatment,two groups of FVC,FEV1,FEV1% indicators were not statistically significant difference(P>0.05).After treatment,there were no significant differences in FVC,FEV1,FEV1% indexes between the two groups and the two groups(P>0.05).6 Serum levels of IL-32 and caspase-16.1IL-32 Before treatment,there was no significant difference in serum IL-32 level between the two groups(P>0.05).After treatment,there was a significant difference in the serum IL-32 level between the two groups(P<0.05).After treatment,the serum level of IL-32 in the experimental group was significantly lower than that before treatment(P<0.05),and the control group was also statistically significant(P<0.05).6.2 Caspase-1 Before treatment,the level of serum Caspase-1 in the two groups was not statistically significant difference Yi(P>0.05).After treatment,there was no significant difference in serum Caspase-1 level between the two groups(P>0.05).After treatment,the serum level of Caspase-1 in the experimental group was significantly lower than that before treatment(P<0.05),and the control group was not statistically significant(P>0.05).Conclusion1 Yi Fei moxibustion can reduce the stable period of COPD patients with acute exacerbation times,reduce clinical symptoms,ease breathing difficulties,increase six minutes walking distance,thus improving the quality of life,enhance the exercise endurance.2 Yi Fei moxibustion can reduce serum IL-32 and caspase-1 levels in patients with stable stage of COPD,and it is speculated that part of the mechanism of therapeutic effect of on the treatment of COPD may be related to the decrease of chronic inflammatory reaction in patients. |
PDF Full Text Request